Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

21 May 2015

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. These data pertain to clinical results from myeloma, synovial sarcoma and ovarian cancer patients who have been dosed with affinity-enhanced, TCR engineered T-cells targeting NY-ESO-1. ASCO brings together more than 30,000 physicians from around the world to discuss state-of-the-art advances and persisting challenges in the field of oncology. The meeting will take place at the McCormick Place exhibition center in Chicago, Illinois on May 29 through June 2, 2015.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting

 

Adaptimmune Announces New Additions to Senior Clinical Management

20 May 2015

Adaptimmune (NASDAQ: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice President, Clinical Development, and Anne-Marie (Annie) Martin, Ph.D. as Vice President, Head of Biomarker Research and Development.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces New Additions to Senior Clinical Management

Adaptimmune Announces Appointment of Vice President of Investor Relations

13 May 2015

Adaptimmune (NASDAQ: ADAP), a clinical stage biotechnology company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President, Investor Relations. 

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Appointment of Vice President of Investor Relations

 

Adaptimmune Announces Closing of Initial Public Offering

11 May 2015

Adaptimmune (NASDAQ: ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. The aggregate net proceeds to Adaptimmune, after underwriting discounts and commissions and estimated offering expenses, were approximately $175.7 million. As previously reported, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 1,687,500 ADSs.

Please click on the link below to download the full Press Release:-

 Adaptimmune Announces Closing of Initial Public Offering

 

 

 

Adaptimmune Announces Pricing of Initial Public Offering

6 May 2015

Adaptimmune Therapeutics plc (Nasdaq: ADAP) today announced the pricing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,687,500 ADSs. The ADSs are expected to begin trading on the NASDAQ Global Select Market under the symbol “ADAP” on May 6, 2015. The offering is expected to close on May 11, 2015, subject to customary closing conditions. Adaptimmune estimates net proceeds from the offering will be approximately $175.7 million.

Please click on the link below to download the full Press Release:-

Adaptimmune Announces Pricing of Initial Public Offering

Adaptimmune appoints Lawrence M. Alleva to its Board of Directors

10 March 2015

Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, today announces the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee.

Please click on the link below to download the full Press Release:-

Adaptimmune appoints Lawrence M. Alleva to its Board of Directors